-77%

est. 2Y upside i

HealthcareSeries A

Canada's digital health clinic for men

Rank

#3183

Sector

Healthtech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Phoenix operates in a growing but increasingly competitive Canadian men's digital health market.

Last updated: March 10, 2026

Bull (10%)+400%

Phoenix successfully fends off competitive threats from Hims & Hers by leveraging its Canadian-specific brand loyalty and regulatory expertise, expanding its service offerings and market penetration to achieve $60M+ ARR by 2028. This strong performance justifies an acquisition by a larger healthcare provider or a successful Series B/C round at a valuation of $800M, representing a significant return.

Base (45%)+50%

Phoenix maintains its position as a key player in the Canadian men's digital health market, growing steadily despite increased competition from Hims & Hers. Revenue reaches approximately $25M ARR by 2028, leading to a Series B round at a valuation of $240M, offering a moderate upside for common shareholders.

Bear (45%)-90%

Hims & Hers' aggressive entry into the Canadian market, particularly with generic semaglutide for weight loss, severely impacts Phoenix's market share and growth, especially in its fastest-growing segment. Phoenix struggles to differentiate, leading to stagnant revenue (e.g., $5M-$8M ARR) and a distressed acquisition or down round at a valuation of $16M-$30M, effectively wiping out most common stock value due to $40M in liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $40M in liquidation preferences, representing 25% of the estimated $160M Series A post-money valuation. This means common shareholders may receive little to nothing in an exit at or below $40M, and significantly reduced returns in exits up to $160M.

Dilution Risk

high

As a Series A company, Phoenix will likely require multiple additional funding rounds (Series B, C, etc.) before a liquidity event, leading to substantial future dilution for current equity holders, especially given increased competitive pressure.

Secondary Liquidity

none

At the Series A stage, there is typically no active secondary market or tender offers for employee equity, meaning liquidity is likely years away.

Marketing — 5 roles

Engineering — 1 role

Operations — 1 role

View all 8 open roles at Phoenix →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Phoenix's data — designed to show you've done your homework.

  • 1

    “How is Phoenix planning to directly counter the aggressive entry of Hims & Hers into the Canadian market, especially in the weight management space with generic semaglutide?”

  • 2

    “Given the current revenue model and SAM of $34M, what are the specific strategies for expanding Phoenix's addressable market and achieving significant revenue scale (e.g., $50M+ ARR) within the next 2-3 years?”

  • 3

    “With $40M in liquidation preferences and the company being a Series A stage, what is the anticipated timeline for a liquidity event (IPO or acquisition), and how is the company planning to manage future dilution for common shareholders?”

Community

Valuation Sentiment

Our model estimates -77% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.